Zhaohong Qin Selected Research

24-dihydroxy-5-cholestane 24-sulfate 3-N-1(spermine)-7

1/2021	Tyrosine phosphatase PTP1B impairs presynaptic NMDA receptor-mediated plasticity in a mouse model of Alzheimer's disease.
1/2021	Ketamine's schizophrenia-like effects are prevented by targeting PTP1B.
10/2020	Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice.
2/2015	Functional properties of Claramine: a novel PTP1B inhibitor and insulin-mimetic compound.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhaohong Qin Research Topics

Disease

5	Stroke (Strokes) 01/2021 - 11/2008
3	Inflammation (Inflammations) 01/2021 - 01/2017
3	Brain Injuries (Brain Injury) 02/2018 - 11/2008
3	Hypoxia (Hypoxemia) 03/2010 - 08/2008
2	Obesity 01/2021 - 07/2013
2	Cognitive Dysfunction 01/2021 - 12/2020
2	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2020
2	Schizophrenia (Dementia Praecox) 01/2021 - 10/2020
2	Infarction (Infarctions) 02/2018 - 01/2017
1	Psychotic Disorders (Schizoaffective Disorder) 01/2021
1	Ischemic Stroke 01/2021
1	Mood Disorders (Mood Disorder) 01/2021
1	Amyloidosis 12/2020
1	Autistic Disorder (Autism) 01/2020
1	Melanoma (Melanoma, Malignant) 02/2018
1	Atherosclerosis 01/2017
1	Weight Loss (Weight Reduction) 02/2015
1	Insulin Resistance 02/2015
1	Hyperphagia (Overeating) 01/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2010
1	Neoplasms (Cancer) 03/2010
1	Cerebral Infarction 11/2008
1	Ischemia 11/2008

Drug/Important Bio-Agent (IBA)

4	24-dihydroxy-5-cholestane 24-sulfate 3-N-1(spermine)-7IBA 01/2021 - 02/2015
4	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021 - 01/2020
3	Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA 01/2021 - 07/2013
2	EndocannabinoidsIBA 01/2021 - 10/2020
2	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 10/2020
2	Proteins (Proteins, Gene)FDA Link 12/2020 - 03/2010
2	Phosphotransferases (Kinase)IBA 10/2020 - 02/2018
2	Neuroprotective AgentsIBA 02/2018 - 03/2010
2	Carrier Proteins (Binding Protein)IBA 01/2017 - 01/2017
1	Ketamine FDA LinkGeneric 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 01/2021
1	salicylhydroxamic acid (SHAM)IBA 01/2021
1	Amyloid beta-PeptidesIBA 01/2021
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 12/2020
1	Glycogen Synthase KinasesIBA 12/2020
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 10/2020
1	tyrosine receptor (receptor, tyrosine)IBA 10/2020
1	CannabinoidsIBA 10/2020
1	ParvalbuminsIBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 02/2018
1	dabrafenibIBA 02/2018
1	CaspasesIBA 02/2018
1	LipopolysaccharidesIBA 02/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2018
1	Death Domain ReceptorsIBA 02/2018
1	Dihydrotachysterol (AT 10)IBA 02/2018
1	erucylphosphocholineIBA 01/2017
1	Prostaglandin D2IBA 01/2017
1	InterferonsIBA 01/2017
1	CytokinesIBA 01/2017
1	Interferon-betaIBA 01/2017
1	Interferon Regulatory Factor-2 (Interferon Regulatory Factor 2)IBA 01/2017
1	claramineIBA 02/2015
1	Calcium Channels (Calcium Channel)IBA 01/2014
1	LeptinIBA 07/2013
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2010
1	Histone Deacetylase 2IBA 03/2010
1	PPAR gammaIBA 11/2008
1	Sulfides (Thioethers)IBA 08/2008

Therapy/Procedure

1	Therapeutics 02/2018
1	Glycemic Control 02/2015